Selinexor Misses Phase 3 Endometrial Cancer Endpoint
Phase 3 XPORT-EC-042 did not meet its primary progression-free-survival endpoint for selinexor maintenance in TP53-wild-type advanced or recurrent endometrial cancer. In the modified intent-to-treat population, median PFS was 12.75 months with selinexor and 7.43…
